TMC435-TiDP16-C117: The Effect of TMC435 on the Results of Electrocardiograms (Electric Recording of the Heart) in Healthy Volunteers

NCT ID: NCT01269294

Last Updated: 2013-05-06

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: PHASE1
• Total Enrollment: 60 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2011-01-31
• Study Completion Date: 2011-07-31

Brief Summary

The purpose of this study is to evaluate the effect of TMC435 on the results of electrocardiograms (ECGs) in healthy volunteers. An electrocardiogram is an electric recording of the heart. TMC435 is being investigated for the treatment of chronic hepatitis C virus infection.

Detailed Description

This is a double-blind, double-dummy, randomized, 4-period cross-over, placebo- and positive-controlled, Phase I study. This means neither the study doctor nor the participants know in which treatment session you will receive which active medication or matching placebo. Every participant will receive 4 treatment sessions (Treatments A, B, C and D) in a different order. The order in which you receive the treatment sessions is determined by chance, like tossing a coin. The purpose of the study is to evaluate the effect of TMC435 on the results of electrocardiograms (electric recording of the heart). Two dose regimens of TMC435 will be tested, ie, 150 mg once daily (the dose that will be given to patients) and 350 mg once daily (a dose higher than the one that will be given to patients), administered for 7 days. A single dose of 400 mg moxifloxacin will be used as a positive control to assess trial sensitivity. The trial population will consist of 60 healthy volunteers of which approximately 18 will be females. In each treatment, dummy capsules will be added in order to have the same number of capsules in each treatment. Treatment A will consist of 150 mg TMC435 once daily for 7 days (2 capsules of TMC435 and 2 capsules placebo on days 1-7, 1 placebo tablet for moxifloxacin on Day 7). Treatment B will consist of 350 mg TMC435 once daily for 7 days (4 capsules of TMC435 on Days 1-7, 1 placebo tablet for moxifloxacin on Day 7). Treatment C will consist of 400 mg moxifloxacin on Day 7 (4 capsules of placebo for TMC435 on Days 1-7, 1 moxifloxacin tablet on Day 7). In Treatment D only placebo will be given (4 capsules of placebo for TMC435 on Days 1-7, 1 placebo tablet for moxifloxacin on Day 7). There will be a washout period of at least 10 days between subsequent treatments. A pharmacogenomic blood sample (DNA sample, blood sample from which your genetic information can be analyzed) will be collected from all volunteers and will be analyzed upon observation of irregular electrocardiogram during the study. The purpose is to see if irregularities in the electrocardiogram can be linked to genetic variants. DNA samples may also be analyzed for additional genes related to pharmacokinetics (what the body does with the drug), pharmacodynamics (what the drug does to your body) or safety and tolerability of TMC435 during the study, as necessary. Two oral doses of TMC435 (150 or 350 mg) or placebo will be given once daily for 7 consecutive days. A single dose of moxifloxacin 400 mg will be administered orally on Day 7 in one of the treatment sessions only.

Conditions

Hepatitis C

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: CROSSOVER
• Primary Study Purpose: TREATMENT
• Blinding Strategy: TRIPLE

Study Groups

001

TMC435 2 capsules of 75 mg once daily for 7 days in Treatment A

Group Type: EXPERIMENTAL

TMC435

Intervention Type: DRUG

2 capsules of 75 mg once daily for 7 days in Treatment A

002

Placebo for TMC435 2 placebo capsules once daily for 7 days in Treatment A

Group Type: OTHER

Placebo for TMC435

Intervention Type: DRUG

2 placebo capsules once daily for 7 days in Treatment A

003

Placebo for moxifloxacin 1 placebo tablet on Day 7 of Treatments A B and D

Group Type: OTHER

Placebo for moxifloxacin

Intervention Type: DRUG

1 placebo tablet on Day 7 of Treatments A, B and D

004

TMC435 2 capsules of 75 mg and 2 capsules of 100 mg once daily for 7 days in Treatment B

Group Type: EXPERIMENTAL

TMC435

Intervention Type: DRUG

2 capsules of 75 mg and 2 capsules of 100 mg once daily for 7 days in Treatment B

005

Placebo for TMC435 4 placebo capsules once daily for 7 days in Treatment C

Group Type: OTHER

Placebo for TMC435

Intervention Type: DRUG

4 placebo capsules once daily for 7 days in Treatment C

006

Moxifloxacin 1 tablet of 400 mg on Day 7 of Treatment C

Group Type: OTHER

Moxifloxacin

Intervention Type: DRUG

1 tablet of 400 mg on Day 7 of Treatment C

007

Placebo for TMC435 4 placebo capsules once daily for 7 days in Treatment D

Group Type: PLACEBO_COMPARATOR

Placebo for TMC435

Intervention Type: DRUG

4 placebo capsules once daily for 7 days in Treatment D

Interventions

TMC435

2 capsules of 75 mg once daily for 7 days in Treatment A

Intervention Type: DRUG

Placebo for TMC435

4 placebo capsules once daily for 7 days in Treatment C

Intervention Type: DRUG

TMC435

2 capsules of 75 mg and 2 capsules of 100 mg once daily for 7 days in Treatment B

Intervention Type: DRUG

Placebo for TMC435

2 placebo capsules once daily for 7 days in Treatment A

Intervention Type: DRUG

Moxifloxacin

1 tablet of 400 mg on Day 7 of Treatment C

Intervention Type: DRUG

Placebo for moxifloxacin

1 placebo tablet on Day 7 of Treatments A, B and D

Intervention Type: DRUG

Placebo for TMC435

4 placebo capsules once daily for 7 days in Treatment D

Intervention Type: DRUG

Eligibility Criteria

Inclusion Criteria

• Non-smokers for at least six months
• Have a body mass index of 18.0 to 30.0 kg per square meter
• Be healthy on the basis of physical examination, medical history, vital signs, and clinical laboratory tests performed at screening.

Exclusion Criteria

• Use of disallowed therapies, including over-the-counter products and dietary supplements
• Any skin condition likely to interfere with ECG electrode placement or adhesion
• History or evidence of current use of alcohol or recreational or narcotic drug use
• Clinically relevant abnormality on ECG at screening or history of clinically relevant heart rhythm disturbances.

• Minimum Eligible Age: 18 Years
• Maximum Eligible Age: 50 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: Yes

Sponsors

Tibotec Pharmaceuticals, Ireland

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Tibotec Pharmaceuticals Clinical Trial

Role: STUDY_DIRECTOR

Tibotec Pharmaceutical Limited

Other Identifiers

TMC435-TiDP16-C117

Identifier Type: OTHER

Identifier Source: secondary_id

CR017491

Identifier Type: -

Identifier Source: org_study_id